Outcomes of patients with technically resectable stage III non-small cell lung cancer treated with concurrent chemoradiation followed by durvalumab consolidation.

Meanwhile, French biotech Sensorion is running a phase 1/2 trial of its SENS-501 (OTOF-GT) candidate and has a candidate for GJB2-related hearing loss in preclinical development.

The biotech acquired DB-OTO as part of its $109 million takeover of Decibel Therapeutics earlier this year, and is also working on candidates for deafness caused by mutations in the GJB2 and STRC ...

Single-cell analysis explores GJB2-mediated interactions in cancer-associated pericyte subgroups that promote lymph node metastasis in lung adenocarcinoma.